The Second Generation of COX-2 Inhibitors: Clinical Pharmacological Point of View

Author(s): D. O. Stichtenoth

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 4 , Issue 6 , 2004

Become EABM
Become Reviewer

Abstract:

Valdecoxib, parecoxib, etoricoxib and lumiracoxib represent the second generation of selective COX-2 inhibitors. In comparison to the first generation, they show an at least equivalent efficacy in the treatment of pain and inflammation. However, the postulated gain of safety is yet difficult to determine and seems to be, if any, small.

Keywords: safety, efficacy, pain, inflammation, valdecoxib, parecoxib, etoricoxib, lumiracoxib

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 4
ISSUE: 6
Year: 2004
Page: [617 - 624]
Pages: 8
DOI: 10.2174/1389557043403783
Price: $65

Article Metrics

PDF: 9